Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients

PURPOSE: Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare genetic syndrome resulting from germline mutations in fumarate hydratase. The combination of bevacizumab plus erlotinib showed promising interim results for HLRCC-associated RCC. Based on these results, we analyzed the out...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Yeonjoo, Keam, Bhumsuk, Kim, Miso, Yoon, Shinkyo, Kim, Dalyong, Choi, Jong Gwon, Seo, Ja Young, Park, Inkeun, Lee, Jae Lyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790829/
https://www.ncbi.nlm.nih.gov/pubmed/30913859
http://dx.doi.org/10.4143/crt.2019.086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790829/
https://www.ncbi.nlm.nih.gov/pubmed/30913859
http://dx.doi.org/10.4143/crt.2019.086

Ejemplares similares